IGF-1 LR3 (1 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously, typically in the morning or post-workout with food intake to mitigate insulin-like effects on blood glucose. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall to avoid foaming; do not shake.
3. Gently swirl or roll until the lyophilized powder dissolves completely into a clear solution.
4. Label the vial with reconstitution date and refrigerate at 2 to 8 °C, protected from light.
5. Use within 30 days of reconstitution; for longer storage, prepare aliquots and freeze at -20 °C for up to 3 to 6 months. At 0.333 mg/mL, 1 unit = 0.01 mL » 3.33 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C or colder in dry, dark conditions for up to 12 months; short-term storage at 2

to 8 °C for several months is acceptable.

• Reconstituted: refrigerate at 2 to 8 °C immediately after mixing; use within 30 days for optimal potency.
• Extended storage: prepare sterile aliquots and freeze at -20 °C; aliquots remain stable for 3 to 6 months.

Never refreeze a thawed vial.

• Allow frozen vials to reach room temperature before opening to minimize condensation; inspect solution

for clarity (discard if cloudy or contains particles).

• Keep all vials protected from light and maintain cold chain during storage.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (IGF-1 LR3, 1 mg each):

• 8 weeks: ~3 vials (~2.24 mg total needed).
• 12 weeks: ~4 vials (~3.64 mg total needed).
• 16 weeks: ~6 vials (~5.04 mg total needed).

Insulin Syringes (U-100, 0.5 mL or 1 mL):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (3 vials): 1 bottle. 12 weeks (4 vials): 2 bottles. 16 weeks (6 vials): 2 bottles.

Alcohol Swabs:

• Per week: 14 swabs. 16 weeks: 224 swabs (3 x 100-count boxes).

Additional:

• Sharps container for safe disposal of used needles and syringes.
• Fast-acting carbohydrate source (glucose tablets or juice) on hand during cycle to address potential

hypoglycemia symptoms, especially during dose titration.

Important Notes

Practical considerations for consistency and safety.

• Sterile technique: Use new sterile insulin syringes for each injection; dispose immediately in a sharps

container.

• Site rotation: Systematically rotate between abdomen, outer thighs, and upper arms.
• Hypoglycemia awareness: Be vigilant for signs of low blood sugar (shakiness, dizziness, sweating)

especially during dose escalation; have fast-acting carbohydrates readily available.

• Timing with meals: Administer with or shortly after food intake to mitigate insulin-like effects on blood

glucose.

• Documentation: Keep a daily log of dose, injection site, and any observed effects.
• Never exceed conservative dosing: Doses above 50 to 60 mcg/day lack robust clinical research

support and may substantially increase adverse effect risk.

How This Works

IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with an N-terminal extension (13 amino acids) and a glutamic acid substitution at position 3, resulting in significantly reduced binding affinity to IGF binding proteins. This modification extends the peptide's half-life from minutes (native IGF-1) to several hours and enhances systemic bioavailability. The extended circulation time allows for once-daily administration protocols in research settings. Unlike native IGF-1, which requires frequent dosing, IGF-1 LR3 maintains more stable plasma levels throughout the day. The peptide exhibits anabolic and metabolic activities through IGF-1 receptor binding, though it has never been approved for therapeutic human use and remains confined to research applications. The insulin-like properties necessitate careful attention to blood glucose management, particularly during initial dosing and titration phases.

Benefits & Side Effects

Observations from preclinical and clinical literature on IGF-1 and its analogs.

• Enhanced anabolic signaling and protein synthesis in target tissues.
• Extended bioavailability compared to native IGF-1 due to reduced binding protein interaction.
• Metabolic effects through IGF-1 receptor pathways.
• Hypoglycemia risk: The most significant concern with IGF-1 LR3 is its insulin-like effect on blood

glucose; symptoms may include shakiness, confusion, sweating, or dizziness. Always administer with

food and monitor for glucose-related symptoms.

• No FDA approval: IGF-1 LR3 has never received regulatory approval for human therapeutic use and is

restricted to research applications.

• Injection site reactions: Mild local irritation, redness, or discomfort may occur.
• Dose-dependent effects: Safety concerns increase substantially at doses exceeding 50 to 60 mcg/day;

conservative dosing strongly recommended.

• Receptor desensitization: Continuous use beyond 6 to 8 weeks may lead to diminished response;

cycling protocols (8 on / 4 to 8 off) are commonly employed.

Lifestyle Factors

Complementary strategies for best outcomes.

• Nutrition: Maintain adequate protein intake (1.6 to 2.2 g/kg body weight); ensure regular meal timing to

manage blood glucose stability.

• Training: Combine resistance training with appropriate recovery periods; IGF-1 signaling pathways are

activated by mechanical loading.

• Sleep & Recovery: Prioritize 7 to 9 hours of quality sleep nightly to optimize endogenous growth factor

production.

• Hydration: Maintain consistent hydration to support metabolic function and peptide distribution.
• Glucose monitoring: Consider periodic blood glucose checks during dose titration.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports (Biomolecules / MDPI).
2. Insulin-like growth factor 1 (IGF-1) and long chain IGF (LR3IGF-1): Medical information (Dopinglinkki / FINCIS).
3. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I for anti-doping purposes (Drug Testing and Analysis).
4. Mecasermin (Subcutaneous): proper use, dosing, and hypoglycemia management (Mayo Clinic / Drugs.com). IGF-1 LR3 (1 mg vial) Once-daily subcutaneous protocol for long-acting IGF-1 analog anabolic and metabolic research. IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified analog of human IGF-1 with significantly extended half-life, studied for its anabolic and metabolic effects. This synthetic variant exhibits reduced binding to IGF binding proteins, allowing enhanced bioavailability and systemic activity. This educational protocol presents a once-daily subcutaneous approach with conservative titration for research applications. Protocol Overview Concise summary of the regimen. Goal: Support anabolic processes and metabolic function through enhanced IGF-1 activity with extended bioavailability. Schedule: Daily subcutaneous injections for 8 weeks (standard cycle); may extend to 12 weeks with appropriate off-periods. Dose Range: 20 to 50 mcg daily with gradual titration; conservative protocols remain at or under 50 mcg/day. Reconstitution: 3.0 mL per 1 mg vial (~0.333 mg/mL or 333 mcg/mL). Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze-thaw cycles. Cycling: Common approach is 8 weeks on, 4 to 8 weeks off to prevent receptor desensitization. Dosing & Reconstitution Guide Standard / gradual approach (3 mL = ~0.333 mg/mL). WEEK DAILY DOSE UNITS PER INJECTION Weeks 1 to 2 20 mcg 6 units (0.06 mL) Weeks 3 to 4 40 mcg 12 units (0.12 mL) Weeks 5 to 8 50 mcg 15 units (0.15 mL) Frequency: Inject once daily subcutaneously, typically in the morning or post-workout with food intake to mitigate insulin-like effects on blood glucose. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability. Reconstitution Steps
5. Draw 3.0 mL bacteriostatic water with a sterile syringe.
6. Inject slowly down the vial wall to avoid foaming; do not shake.
7. Gently swirl or roll until the lyophilized powder dissolves completely into a clear solution.
8. Label the vial with reconstitution date and refrigerate at 2 to 8 °C, protected from light.
9. Use within 30 days of reconstitution; for longer storage, prepare aliquots and freeze at -20 °C. At 0.333 mg/mL, 1 unit = 0.01 mL » 3.33 mcg on a U-100 insulin syringe. Storage Instructions Proper storage preserves peptide quality. • Lyophilized (unopened): store at -20 °C or colder (-80 °C optimal) in dry, dark conditions for up to 12 months. • Reconstituted: refrigerate at 2 to 8 °C; use within 30 days for optimal potency. • Extended storage: prepare sterile aliquots and freeze at -20 °C; aliquots remain stable for 3 to 6 months. Never refreeze a thawed vial. • Allow frozen vials to reach room temperature before opening; inspect solution for clarity (discard if cloudy). Supplies Needed Plan based on an 8 to 16 week daily protocol with gradual titration. Peptide Vials (IGF-1 LR3, 1 mg each): • 8 weeks: ~3 vials (~2.24 mg total needed). • 12 weeks: ~4 vials (~3.64 mg total needed). • 16 weeks: ~6 vials (~5.04 mg total needed). Insulin Syringes (U-100, 0.5 mL or 1 mL): • Per week: 7 syringes (1/day). • 8 weeks: 56. 12 weeks: 84. 16 weeks: 112. Bacteriostatic Water (10 mL bottles): • 8 weeks (3 vials): 1 bottle. 12 weeks (4 vials): 2 bottles. 16 weeks (6 vials): 2 bottles. Alcohol Swabs: • Per week: 14 swabs. • 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count). Fast-acting carbohydrate source: • Glucose tablets or juice on hand during cycle to address potential hypoglycemia symptoms, especially during dose titration. Important Notes Practical considerations for consistency and safety. • Sterile technique: always use new, sterile insulin syringes; dispose immediately in a sharps container. • Site rotation: systematically rotate between abdomen, outer thighs, and upper arms to reduce local irritation. • Injection technique: inject slowly and steadily; wait a few seconds before withdrawing. • Hypoglycemia awareness: be vigilant for signs of low blood sugar (shakiness, dizziness, sweating) especially during dose escalation; have fast-acting carbohydrates readily available. • Timing with meals: administer with or shortly after food intake to mitigate insulin-like effects on blood glucose. • Never exceed conservative dosing: doses above 50 to 60 mcg/day lack robust clinical research support and may substantially increase adverse effect risk. How This Works IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with an N-terminal extension (13 amino acids) and a glutamic acid substitution at position 3, resulting in significantly reduced binding affinity to IGF binding proteins. This modification extends the peptide's half-life from minutes (native IGF-1) to several hours and enhances systemic bioavailability. The extended circulation time allows for once-daily administration protocols in research settings. Unlike native IGF-1, which requires frequent dosing, IGF-1 LR3 maintains more stable plasma levels throughout the day. The peptide exhibits anabolic and metabolic activities through IGF-1 receptor binding, though it has never been approved for therapeutic human use and remains confined to research applications. Potential Benefits and Side Effects Observations from preclinical and clinical literature on IGF-1 and its analogs. • Enhanced anabolic signaling and protein synthesis in target tissues. • Extended bioavailability compared to native IGF-1 due to reduced binding protein interaction. • Metabolic effects through IGF-1 receptor pathways. • Hypoglycemia risk: the most significant concern is its insulin-like effect on blood glucose; symptoms may include shakiness, confusion, sweating, or dizziness. • No FDA approval: IGF-1 LR3 has never received regulatory approval for human therapeutic use. • Injection site reactions: mild local irritation, redness, or discomfort may occur. • Dose-dependent effects: safety concerns increase substantially at doses exceeding 50 to 60 mcg/day; conservative dosing protocols are strongly recommended. • Receptor desensitization: continuous use beyond 6 to 8 weeks may lead to diminished response; cycling protocols are commonly employed. Lifestyle Factors Complementary strategies for best outcomes. • Nutrition: maintain adequate protein intake (1.6 to 2.2 g/kg body weight); ensure regular meal timing to manage blood glucose stability. • Training: combine resistance training protocols with appropriate recovery periods; IGF-1 signaling is activated by mechanical loading. • Sleep & Recovery: prioritize 7 to 9 hours of quality sleep nightly. • Hydration: maintain consistent hydration status to support metabolic function and peptide distribution. • Glucose monitoring: consider periodic blood glucose checks during dose titration. Injection Technique General subcutaneous guidance from clinical best-practice resources.
10. Clean the vial stopper and skin with alcohol; allow to dry.
11. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
12. Do not aspirate for subcutaneous injections; inject slowly and steadily.
13. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
14. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy. Recommended Source NTN Performance recommends Amino Club for high-purity IGF-1 LR3 (1 mg). If unavailable at Amino Club, our trusted backup is ION Peptide. Why Amino Club? • Lab-verified purity with batch Certificates of Analysis. • Consistent handling and documentation standards. • Reliable fulfillment with cold-chain integrity. Primary: IGF-1 LR3 at Amino Club (code PROFIT). Backup: IGF-1 LR3 at ION Peptide (code PROFIT). References Source citations for further reading.
15. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports (Biomolecules / MDPI).
16. Insulin-like growth factor 1 (IGF-1) and long chain IGF (LR3IGF-1) (Dopinglinkki / FINCIS).
17. Insulin-Like Growth Factor-1: A Promising Therapeutic Target for Peripheral Nerve Injury (Frontiers in Bioengineering & Biotechnology).
18. Detection of LongR3-IGF-I and analogs using mass spectrometry (Drug Testing and Analysis). IGF-1 LR3 (1 mg vial) Once-daily subcutaneous protocol for extended-half-life IGF-1 analog research. IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified analog of human IGF-1 with significantly extended half-life, studied for its anabolic and metabolic effects. This synthetic variant exhibits reduced binding to IGF binding proteins, allowing enhanced bioavailability and systemic activity. This educational protocol presents a once-daily subcutaneous approach with conservative titration for research applications. Protocol Overview Concise summary of the regimen. Goal: Support anabolic processes and metabolic function through enhanced IGF-1 activity with extended bioavailability. Schedule: Daily subcutaneous injections for 8 weeks (standard cycle); may extend to 12 weeks with appropriate off-periods. Dose Range: 20 to 50 mcg daily with gradual titration; conservative protocols remain at or under 50 mcg/day. Reconstitution: 3.0 mL per 1 mg vial (~0.333 mg/mL or 333 mcg/mL). Cycling: Common approach is 8 weeks on, 4 to 8 weeks off to prevent receptor desensitization. Dosing & Reconstitution Guide Standard / gradual approach (3 mL = ~0.333 mg/mL). WEEK DAILY DOSE UNITS PER INJECTION Weeks 1 to 2 20 mcg 6 units (0.06 mL) Weeks 3 to 4 40 mcg 12 units (0.12 mL) Weeks 5 to 8 50 mcg 15 units (0.15 mL) Frequency: Inject once daily subcutaneously, typically in the morning or post-workout with food intake to mitigate insulin-like effects on blood glucose. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability. Reconstitution Steps
19. Draw 3.0 mL bacteriostatic water with a sterile syringe.
20. Inject slowly down the vial wall to avoid foaming; do not shake.
21. Gently swirl until the lyophilized powder dissolves completely into a clear solution.
22. Label the vial with reconstitution date and refrigerate at 2 to 8 °C, protected from light.
23. Use within 30 days of reconstitution; for longer storage, prepare aliquots and freeze at -20 °C for up to 3 to 6 months. At 0.333 mg/mL, 1 unit = 0.01 mL » 3.33 mcg on a U-100 insulin syringe. Storage Instructions Proper storage preserves peptide quality. • Lyophilized (unopened): store at -20 °C or colder in dry, dark conditions for up to 12 months; short-term storage at 2 to 8 °C for several months is acceptable. • Reconstituted solution: refrigerate at 2 to 8 °C immediately after mixing; use within 30 days for optimal potency. • Extended storage: for storage beyond 30 days, prepare sterile aliquots and freeze at -20 °C; aliquots remain stable for 3 to 6 months. Never refreeze a thawed vial. • Allow frozen vials to reach room temperature before opening; inspect for clarity (discard if cloudy or contains particles). Protect from light. Supplies Needed Plan based on an 8 to 16 week daily protocol with gradual titration. Peptide Vials (IGF-1 LR3, 1 mg each): • 8 weeks: ~3 vials (~2.24 mg total needed). • 12 weeks: ~4 vials (~3.64 mg total needed). • 16 weeks: ~6 vials (~5.04 mg total needed). Insulin Syringes (U-100, 0.5 mL or 1 mL): • Per week: 7 syringes (1/day). • 8 weeks: 56. 12 weeks: 84. 16 weeks: 112. Bacteriostatic Water (10 mL bottles): • 8 weeks (3 vials): 1 bottle. 12 weeks (4 vials): 2 bottles. 16 weeks (6 vials): 2 bottles. Alcohol Swabs: • Per week: 14 swabs. • 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count). Fast-acting carbohydrate source: • Glucose tablets or juice on hand to address potential hypoglycemia symptoms, especially during dose titration. Important Notes Practical considerations for consistency and safety. • Sterile technique: always use new, sterile insulin syringes for each injection; dispose immediately in a sharps container. • Site rotation: systematically rotate between abdomen (at least 2 inches from navel), outer thighs, and upper arms. • Injection technique: inject slowly and steadily; wait a few seconds before withdrawing the needle. • Hypoglycemia awareness: be vigilant for signs of low blood sugar (shakiness, dizziness, sweating) during dose escalation; keep fast-acting carbohydrates available. • Timing with meals: administer with or shortly after food intake to mitigate insulin-like effects on blood glucose. • Documentation: keep a daily log of dose, injection site, and any observed effects. • Never exceed conservative dosing: doses above 50 to 60 mcg/day lack robust clinical research support and may substantially increase adverse effect risk. How This Works IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with an N-terminal extension (13 amino acids) and a glutamic acid substitution at position 3, resulting in significantly reduced binding affinity to IGF binding proteins. This modification extends the peptide's half-life from minutes (native IGF-1) to several hours and enhances systemic bioavailability. The extended circulation time allows for once-daily administration protocols in research settings. Unlike native IGF-1, which requires frequent dosing, IGF-1 LR3 maintains more stable plasma levels throughout the day. The peptide exhibits anabolic and metabolic activities through IGF-1 receptor binding, though it has never been approved for therapeutic human use and remains confined to research applications. The insulin-like properties necessitate careful attention to blood glucose management, particularly during initial dosing and titration phases. Potential Benefits and Side Effects Observations from preclinical and clinical literature on IGF-1 and its analogs. • Enhanced anabolic signaling: and protein synthesis in target tissues. • Extended bioavailability: compared to native IGF-1 due to reduced binding protein interaction. • Metabolic effects: through IGF-1 receptor pathways. • Hypoglycemia risk: the most significant concern; symptoms may include shakiness, confusion, sweating, or dizziness. Always administer with food and monitor for glucose-related symptoms. • No FDA approval: IGF-1 LR3 has never received regulatory approval for human therapeutic use and is restricted to research applications. • Injection site reactions: mild local irritation, redness, or discomfort may occur. • Dose-dependent effects: safety concerns increase substantially at doses exceeding 50 to 60 mcg/day; conservative dosing is strongly recommended. • Receptor desensitization: continuous use beyond 6 to 8 weeks may lead to diminished response; cycling protocols (8 weeks on, 4 to 8 weeks off) are commonly employed. Lifestyle Factors Complementary strategies for best outcomes. • Nutrition: maintain adequate protein intake (1.6 to 2.2 g/kg body weight); ensure regular meal timing to manage blood glucose stability. • Training: combine resistance training with appropriate recovery periods; IGF-1 signaling pathways are activated by mechanical loading. • Sleep & recovery: prioritize 7 to 9 hours of quality sleep to optimize endogenous growth factor production. • Hydration: maintain consistent hydration status to support metabolic function and peptide distribution. • Glucose monitoring: consider periodic blood glucose checks during dose titration, especially if experiencing any hypoglycemic symptoms. Injection Technique General subcutaneous guidance from clinical best-practice resources.
24. Clean the vial stopper and skin with alcohol; allow to dry.
25. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
26. Do not aspirate for subcutaneous injections; inject slowly and steadily.
27. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
28. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy. Recommended Source NTN Performance recommends Amino Club for high-purity IGF-1 LR3 (1 mg). If unavailable at Amino Club, our trusted backup is ION Peptide. Why Amino Club? • Lab-verified purity with batch Certificates of Analysis. • Consistent handling and documentation standards. • Reliable fulfillment with cold-chain integrity. Primary: IGF-1 LR3 at Amino Club (code PROFIT). Backup: IGF-1 LR3 at ION Peptide (code PROFIT). References Source citations for further reading.
29. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports (Biomolecules, MDPI).
30. Insulin-like growth factor 1 (IGF-1) and long chain IGF (LR3IGF-1): Medical information (Dopinglinkki / FINCIS).
31. Mecasermin (Subcutaneous route): Proper Use (Mayo Clinic / IBM Micromedex).
32. Detection of LongR3-IGF-I using immunopurification and high resolution mass spectrometry (Drug Testing and Analysis).